On February 11, 2021 Quell Therapeutics Ltd ("Quell"), a biotechnology company developing engineered T regulatory (Treg) cell therapies, reported the closing of an extended Series A financing led by their existing investors Syncona Ltd, who have committed an additional $34.7 million and UCL Technology Fund who have committed an additional $1 million; bringing the total Series A financing to circa $84 million (Press release, UCLB, FEB 11, 2021, View Source [SID1234574903]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!